p73 and MDM2 confer the resistance of epidermoid carcinoma to cisplatin by blocking

被引:15
|
作者
Hayashi, Syunji
Ozaki, Toshinori
Yoshida, Kaori
Hosoda, Mitsuchika
Todo, Satoru
Akiyama, Shin-ichi
Nakagawara, Akira [1 ]
机构
[1] Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan
[2] Hokkaido Univ, Sch Med, Kita Ku, Dept Gen Surg, Sapporo, Hokkaido 0608638, Japan
[3] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Mol Oncol, Kagoshima 8908520, Japan
基金
日本学术振兴会;
关键词
cisplatin; KB-3-1; MDM2; p53; p73;
D O I
10.1016/j.bbrc.2006.06.095
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
p73 responds to DNA damage and exerts its pro-apoptotic function. However, p73 might contribute to the development of drug-resistance in certain tumor cells. In this study, we found that p73 and MDM2 correlate with cisplatin-resistant phenotype of human epidermoid carcinoma-derived cells. p73 and MDM2 were kept at low levels in the cisplatin-sensitive KB-3-1 cells, whereas p53 was induced to be phosphorylated at Ser-15 in response to cisplatin. In contrast, p73 and MDM2 were expressed at higher levels, and cisplatin-mediated p53 phosphorylation was undetectable in the cisplatin-resistant KCP-4 cells. Enforced expression of p73 in KB-3-1 cells caused an accumulation of unphosphorylated form of p53 and MDM2, and conferred the cisplatin resistance. Collectively, our results suggest that a loss of the cisplatin sensitivity is at least in part due to a lack of cisplatin-induced p53 phosphorylation, and p73 might cooperate with MDM2 to be involved in this process. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 50 条
  • [1] MDM2 suppresses p73 function without promoting p73 degradation
    Lu, H
    Zeng, X
    Chen, L
    Jost, CA
    Maya, R
    Keller, D
    Wang, X
    Kaelin, WG
    Oren, M
    Chen, J
    [J]. FASEB JOURNAL, 1999, 13 (07): : A1538 - A1538
  • [2] MDM2 suppresses p73 function without promoting p73 degradation
    Zeng, XY
    Chen, LH
    Jost, CA
    Maya, R
    Keller, D
    Wang, XJ
    Kaelin, WG
    Oren, M
    Chen, JD
    Lu, H
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1999, 19 (05) : 3257 - 3266
  • [3] Mdm2 binds p73α without targeting degradation
    Eva Bálint
    Stewart Bates
    Karen H Vousden
    [J]. Oncogene, 1999, 18 : 3923 - 3929
  • [4] MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function
    Wu, Hong
    Leng, Roger P.
    [J]. ONCOTARGET, 2015, 6 (25) : 21479 - 21492
  • [5] Mdm2 binds p73α without targeting degradation
    Bálint, E
    Bates, S
    Vousden, KH
    [J]. ONCOGENE, 1999, 18 (27) : 3923 - 3929
  • [6] The Expression of P73, P21 and MDM2 Proteins in Gliomas
    Makoto Kamiya
    Yoichi Nakazato
    [J]. Journal of Neuro-Oncology, 2002, 59 : 143 - 149
  • [7] The expression of p73, p21 and MDM2 proteins in gliomas
    Kamiya, M
    Nakazato, Y
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2002, 59 (02) : 143 - 149
  • [8] Subcellular distribution of p53 and p73 are differentially regulated by MDM2
    Gu, JJ
    Nie, LH
    Kawai, H
    Yuan, ZM
    [J]. CANCER RESEARCH, 2001, 61 (18) : 6703 - 6707
  • [9] Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer
    Jun, Hee Jung
    Park, Sun Ha
    Lee, Won Kee
    Choi, Jin Eun
    Jang, Jin Sung
    Kim, Eun Jin
    Cha, Sung Ick
    Kim, Dong Sun
    Kam, Sin
    Kim, Chang Ho
    Kang, Young Mo
    Jung, Tae Hoon
    Park, Jae Yong
    [J]. MOLECULAR CARCINOGENESIS, 2007, 46 (02) : 100 - 105
  • [10] A possible role of p73 on the modulation of p53 level through MDM2
    Wang, XQ
    Ongkeko, WM
    Lau, AWS
    Leung, KM
    Poon, RYC
    [J]. CANCER RESEARCH, 2001, 61 (04) : 1598 - 1603